Focused On-demand Library for Cytosolic 5'-nucleotidase 1A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9BXI3

UPID:

5NT1A_HUMAN

Alternative names:

5'-deoxynucleotidase; Cytosolic 5'-nucleotidase IA

Alternative UPACC:

Q9BXI3; Q3SYB9; Q5TG98; Q9BWT8

Background:

Cytosolic 5'-nucleotidase 1A, also known as 5'-deoxynucleotidase, plays a crucial role in nucleotide metabolism by catalyzing the hydrolysis of ribonucleotide and deoxyribonucleotide monophosphates. This enzyme efficiently processes AMP, dCMP, and IMP into inorganic phosphate and the corresponding nucleoside, serving as a pivotal regulator in the nucleotide salvage pathway.

Therapeutic significance:

Understanding the role of Cytosolic 5'-nucleotidase 1A could open doors to potential therapeutic strategies. Its involvement in nucleotide metabolism suggests its potential impact on cellular energy balance and nucleotide pool homeostasis, making it a target of interest in metabolic disorders and cancer research.